Business Details
36 Years
experience
Healthcare Investment & Development Experts in Fort Worth
Founded in 1990, DFB Pharmaceuticals has established itself as a leader in healthcare innovation through strategic investment and development. Our entrepreneurial approach focuses on identifying and advancing groundbreaking technologies that address critical unmet medical needs. Over three decades, we have built a proven track record of creating value through strategic acquisitions, internal product development, and operational excellence in life sciences. Our portfolio includes successful ventures in wound care, dermatology, surgical antisepsis, and oncology, with landmark achievements such as the development of novel topical pharmaceuticals and the commercialization of plant cell fermentation technology. Today, we continue to drive innovation through subsidiaries like NanOlogy, which pioneers intratumoral cancer therapies, and Phyton Biotech, the global leader in plant-derived active pharmaceutical ingredients.Our team combines deep industry expertise with a commitment to sustainability and environmental responsibility, exemplified by Phyton's yew tree-free paclitaxel production. With a history of over $1.5 billion realized from successful exits, we maintain a flexible, partnership-driven model that fosters long-term relationships with academic institutions, corporate partners, and clinical experts. Our leadership team brings decades of executive experience from industry giants like Johnson & Johnson and Baxter, ensuring rigorous scientific and business standards. We remain dedicated to transforming healthcare through practical innovations that improve patient outcomes while maintaining strict regulatory compliance and ethical practices. This enduring commitment positions us to continue delivering impactful solutions in oncology and beyond.
Services
Healthcare investment
Pharmaceutical development
Oncology therapies
API manufacturing
Infection control products
Plant cell fermentation
Clinical research
Strategic acquisitions
Drug formulation
Global distribution
Details
- Year established: 1990
Highlights and features
- We have over 30 years of experience in healthcare investment and development
- Our team includes executives with prior leadership roles at Johnson & Johnson and Baxter
- We pioneered plant cell fermentation technology for sustainable pharmaceutical production
- Our portfolio companies have achieved over $1.5 billion in realized value
- We maintain global partnerships for oncology research and product distribution
Services
Healthcare investment
DFB Pharmaceuticals specializes in strategic healthcare investment through targeted acquisitions and development of life science companies. Our approach combines entrepreneurial vision with proven operational expertise to build value in pharmaceutical and biotechnology sectors. We focus on opportunities that address unmet medical needs while maintaining strong returns for stakeholders.
Oncology therapies
Through NanOlogy subsidiary, we develop innovative intratumoral cancer therapies using patented particle engineering technology. Our approach delivers targeted treatment directly to solid tumors while minimizing systemic toxicity. Clinical programs focus on multiple tumor types with ongoing trials demonstrating our commitment to advancing oncology care.
API manufacturing
Phyton Biotech, our wholly-owned subsidiary, leads global production of paclitaxel and docetaxel active pharmaceutical ingredients. Using proprietary plant cell fermentation technology, we provide sustainable, high-quality cancer treatment components without reliance on traditional yew tree sources, ensuring environmental responsibility and supply chain stability.
Infection control
Our infection control portfolio features Aldahol, a high-level disinfectant combining isopropanol and glutaraldehyde for enhanced efficacy. This innovative formulation provides fast-acting, room-temperature sterilization of surgical equipment, addressing critical needs in healthcare facility infection prevention protocols across global markets.
Plant cell fermentation
We pioneered plant cell fermentation technology for pharmaceutical production, creating sustainable alternatives to traditional plant harvesting methods. This proprietary process enables large-scale manufacturing of complex plant-derived compounds for oncology, nutraceutical, and specialty medicine applications while maintaining strict quality control standards.
People
H. Paul Dorman
Chairman and CEO
Founder of DFB Pharmaceuticals with 30+ years leading healthcare investments. Previously held executive roles at Johnson & Johnson and Baxter. Holds engineering and law degrees from Tulane and Loyola Universities. Serves on multiple industry boards.
Mark A. Mitchell
Chief Legal Officer
25+ years pharmaceutical industry experience including executive roles at DFB since 1993. Serves on Phyton Biotech and Nanology management teams. Former corporate lawyer with SMU law degree. Oversees legal, regulatory, and compliance functions across portfolio companies.
Maxwell Lea
Managing Director
Leads business development and investment strategy at DFB. Former investment banker with Bank of America Securities. Holds MBA from Duke University and BA from Vanderbilt. Oversees corporate finance and strategic planning for portfolio companies.
Marc A. Iacobucci
Managing Director
28-year DFB veteran with leadership roles in business development and operations. Oversees NanOlogy's clinical programs. Former clinical pharmacist and pharmaceutical representative. Holds MBA from University of Texas and pharmacy degree from Ohio State.
Questions
What areas of healthcare does DFB focus on?
We specialize in oncology, pharmaceutical manufacturing, infection control, and plant cell fermentation technology through our subsidiaries.
What makes Phyton Biotech unique?
Phyton is the world's first company using plant cell fermentation to produce cancer treatment ingredients without relying on yew trees.
What clinical trials are currently underway?
NanOlogy has completed 7 Phase 1/2 trials and is initiating late-phase research for solid tumor treatments, including pediatric brain cancer studies.
Where are DFB's manufacturing facilities located?
We operate facilities in Texas, Germany, Canada, and China through our portfolio companies and partners.
What investment opportunities does DFB offer?
We seek partnerships in oncology, biotechnology, and pharmaceutical development with focus on innovative technologies and unmet medical needs.
